ResMed (RMD) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
26 Oct, 2026Executive summary
Annual meeting scheduled for Nov. 16, 2023, at 12:00 p.m. U.S. Pacific Time and Nov. 17 at 7:00 a.m. Australian Eastern Time, via live webcast.
Shareholders were asked to vote on director elections, auditor ratification, executive compensation, and the frequency of future say-on-pay votes.
Voting matters and shareholder proposals
Four voting matters: elect ten directors, ratify KPMG LLP, approve advisory say-on-pay, and set the frequency of future say-on-pay votes.
Board recommended voting For the director nominees, auditor ratification, and say-on-pay; it recommended annual say-on-pay votes (“Year”).
Board of directors and corporate governance
Ten nominees—Carol Burt, Jan De Witte, Karen Drexler, Michael Farrell, Peter Farrell, Harjit Gill, John Hernandez, Richard Sulpizio, Desney Tan, and Ronald Taylor—stood for election through the 2024 annual meeting and until successors are elected and qualified.
Latest events from ResMed
- Revenue rose 7% core CC, EPS 14%, and shareholder returns topped $1.0B.RMD
Q1 2027 - Shareholders were asked to elect 10 directors, ratify KPMG, and approve executive pay.RMD
Proxy Filing - Board backs all three proposals: elect 11 directors, ratify KPMG and approve say-on-pay.RMD
Proxy Filing - Board backs all agenda items, including 11 director nominees and two employee plan amendments.RMD
Proxy Filing - 2026 saw strong growth, strategic investments, and enhanced sustainability and governance.RMD
Stewardship presentation - FY26 saw 8% revenue growth, 16% EPS growth, and $1B returned to shareholders.RMD
Corporate presentation - Volume-driven growth, digital engagement, and portfolio shifts drive robust outlook.RMD
Morgan Stanley 24th Annual Global Healthcare Conference - FY26 revenue grew 8% to $5.7B, with strong margins, digital innovation, and increased shareholder returns.RMD
Corporate presentation - Record FY26 growth, margin expansion, and $1.85B+ FY27 capital returns planned.RMD
Q4 2026